Sharon Mates sells 28,680 shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Your Free Report ) CEO Sharon Mates sold 28,680 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $79,696,697.34. The sale was disclosed in a filing with the SEC, which is available at this link.

Sharon Mates also recently made the following transactions:

• On Wednesday, August 21st, Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45.

Price performance of intracellular therapies

Shares of Intra-Cellular Therapies stock opened at $74.48 on Friday. The company has a 50-day moving average price of $75.06 and a 200-day moving average price of $71.11. The company has a market cap of $7.86 billion, a P/E ratio of -64.21 and a beta of 1.01. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report ) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The company had revenue of $161.40 million during the quarter, compared to analysts’ expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The company’s revenue for the quarter was up 45.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.45) earnings per share. As a group, research analysts expect that Intra-Cellular Therapies, Inc. to post -0.54 EPS for the current fiscal year.

Institutional inputs and outputs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kapitalo Investimentos Ltda acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at about $26,000. Headlands Technologies LLC purchased a new stake in Intracellular Therapies in the 1st quarter valued at about $32,000. Signaturefd LLC raised its stake in Intracellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 239 shares during the period. Fidelis Capital Partners LLC acquired a new position in Intra-Cellular Therapies in the first quarter valued at $53,000. Finally, Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies in the second quarter worth $56,000. 92.33% of the shares are currently owned by hedge funds and other institutional investors.

Analyst upgrades and downgrades

A number of equities analysts have commented on ITCI shares. UBS Group decreased their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald boosted their price objective on shares of Intra-Cellular Therapies from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday. Mizuho upped their price objective on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Finally, Goldman Sachs Group reduced their price objective on shares of Intracellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research report on Thursday, 8 August. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Moderate Buy” and a consensus price target of $97.00, according to MarketBeat.com.

Get the latest stock report on ITCI

Intracellular Therapies Company Profile

(Get a free report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development and commercialization of small molecule drugs that address unmet medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS ) in the United States.

Read more

Receive daily news and reviews for intracellular therapies – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intracellular Therapies and related companies with MarketBeat.com’s FREE daily email newsletter.